After a massive rally, Facebook stock has remained subdued despite strong earnings.
It has been a very good year for Facebook Inc (NASDAQ:FB) stock investors. The shares of eCommerce giant have delivered over 55% return this year, outperforming widely outperforming the Nasdaq Composite. Not only that, Facebook stock is also one of the best performersin the so-called’FAANG’ grouping comprising of tech giants like Apple, Amazon, Netflix and Microsoft. Only Netflix stock has performed better, that too by a slight margin.
Hot Performing Stocks To Own For 2018: Enphase Energy, Inc.(ENPH)
- [By Ben Levisohn]
UPDATE: I stand corrected. There does appear to be a reason for First Solar’s market-leading move today. Axiom Capital’s Gordon Johnson attributes the rise to the $10 million investment in Enphase Energy (ENPH), which makes “microinverter systems for the solar photovoltaic industry,” by investors T.J. Rodgers and John Doerr.
Hot Performing Stocks To Own For 2018: New York Community Bancorp, Inc.(NYCB)
- [By Paul Ausick]
New York Community Bank Inc. (NYSE: NYCB) dropped 5% Wednesday to post a new low of $13.05 after closing at $13.74 Tuesday night. The stock’s 52-week high is $17.68. Volume was about 80% above the daily average of around 4.8 million shares. The bank reported disappointing results this morning.
Hot Performing Stocks To Own For 2018: SPDR S&P Biotech ETF (XBI)
- [By ]
The SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels back in mid-November.
- [By ]
And while the big drug companies will experience a significant adjustment, biotech companies, with their focus on long term results and outright cures in some cases, are probably poised to perform. The best way to get invested would be with the Biotech Spider ETF (NYSE: XBI).
- [By ]
After sneaking lower to begin the new trading week, the SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels.
- [By WWW.KIPLINGER.COM]
Theres been follow-up, too: Valeant Pharmaceuticals Intl Inc (VRX) had to face the Senate in April for aggressively hiking prices on its drugs. Now Mylan NV (MYL) is answering to the government soon after a story showed that EpiPen prices have rocketed 400% since 2008 with no significant improvements to the treatment. This scandal, too, is rocking biotechs including (Link]recommendation SPDR S&P Biotech ETF (XBI).